143 related articles for article (PubMed ID: 32362156)
21. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.
Zhou Z; Fan Y; Tang W; Liu X; Thomason D; Zhou ZY; Macaulay D; Fischer A
J Rheumatol; 2019 Aug; 46(8):920-927. PubMed ID: 30770505
[TBL] [Abstract][Full Text] [Related]
22. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
23. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
[TBL] [Abstract][Full Text] [Related]
24. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
25. Understanding healthcare burden and treatment patterns among young adults with schizophrenia.
Huang A; Amos TB; Joshi K; Wang L; Nash A
J Med Econ; 2018 Oct; 21(10):1026-1035. PubMed ID: 30001651
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.
To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R
J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423
[TBL] [Abstract][Full Text] [Related]
27. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
[TBL] [Abstract][Full Text] [Related]
28. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
29. Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee.
Chen F; Su W; Bedenbaugh AV; Oruc A
J Med Econ; 2020 Oct; 23(10):1151-1158. PubMed ID: 32715848
[TBL] [Abstract][Full Text] [Related]
30. Economic burden of osteoporotic fractures in US managed care enrollees.
Williams SA; Chastek B; Sundquist K; Barrera-Sierra S; Leader D; Weiss RJ; Wang Y; Curtis JR
Am J Manag Care; 2020 May; 26(5):e142-e149. PubMed ID: 32436682
[TBL] [Abstract][Full Text] [Related]
31. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
32. Burden of venous leg ulcers in the United States.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
[TBL] [Abstract][Full Text] [Related]
33. Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database.
Zhao Z; Zhu Y; Fang Y; Ye W; McCollam P
J Med Econ; 2015; 18(9):655-65. PubMed ID: 25891183
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
35. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis.
Weycker D; Hanau A; Hatfield M; Wu H; Sharma A; Bensink ME; Chandler D; Grossman A; Tarantino M
J Med Econ; 2020 Feb; 23(2):184-192. PubMed ID: 31547724
[No Abstract] [Full Text] [Related]
36. Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin.
Blaylock B; Epstein J; Stickler P
J Med Econ; 2020 Jun; 23(6):537-545. PubMed ID: 31999204
[No Abstract] [Full Text] [Related]
37. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
[TBL] [Abstract][Full Text] [Related]
38. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
[No Abstract] [Full Text] [Related]
39. Healthcare utilization and costs with fixed-source versus variable-source tacrolimus in patients receiving a kidney transplant.
Bunniran S; Lee E; Kamble P; Suehs B; Franks B; Schwartz J; Thal G; Spalding J
J Med Econ; 2018 Nov; 21(11):1067-1074. PubMed ID: 30032686
[TBL] [Abstract][Full Text] [Related]
40. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
